Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
MNTA's Cash-to-Debt is ranked higher than
99% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. MNTA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MNTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 13.61  Med: 71.35 Max: No Debt
Current: No Debt
Equity-to-Asset 0.78
MNTA's Equity-to-Asset is ranked higher than
78% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MNTA: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
MNTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.86  Med: 0.85 Max: 0.96
Current: 0.78
-0.86
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
99% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. MNTA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNTA' s Interest Coverage Range Over the Past 10 Years
Min: 110.84  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 7.13
Beneish M-Score: -1.07
WACC vs ROIC
17.13%
-634.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -68.17
MNTA's Operating Margin % is ranked lower than
86% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. MNTA: -68.17 )
Ranked among companies with meaningful Operating Margin % only.
MNTA' s Operating Margin % Range Over the Past 10 Years
Min: -448.33  Med: -142.21 Max: 63.48
Current: -68.17
-448.33
63.48
Net Margin % -19.16
MNTA's Net Margin % is ranked lower than
87% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. MNTA: -19.16 )
Ranked among companies with meaningful Net Margin % only.
MNTA' s Net Margin % Range Over the Past 10 Years
Min: -429.9  Med: -140.82 Max: 63.71
Current: -19.16
-429.9
63.71
ROE % -5.99
MNTA's ROE % is ranked lower than
82% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. MNTA: -5.99 )
Ranked among companies with meaningful ROE % only.
MNTA' s ROE % Range Over the Past 10 Years
Min: -66.11  Med: -31.66 Max: 59.21
Current: -5.99
-66.11
59.21
ROA % -4.84
MNTA's ROA % is ranked lower than
81% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. MNTA: -4.84 )
Ranked among companies with meaningful ROA % only.
MNTA' s ROA % Range Over the Past 10 Years
Min: -51.08  Med: -27.29 Max: 55.62
Current: -4.84
-51.08
55.62
ROC (Joel Greenblatt) % -339.83
MNTA's ROC (Joel Greenblatt) % is ranked lower than
87% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. MNTA: -339.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -529.82  Med: -376.75 Max: 349.83
Current: -339.83
-529.82
349.83
3-Year Revenue Growth Rate 31.80
MNTA's 3-Year Revenue Growth Rate is ranked lower than
57% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. MNTA: 31.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MNTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.8 Max: 139.6
Current: 31.8
0
139.6
3-Year EBITDA Growth Rate -18.30
MNTA's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. MNTA: -18.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.2  Med: -9 Max: 30.4
Current: -18.3
-45.2
30.4
3-Year EPS without NRI Growth Rate -47.40
MNTA's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. MNTA: -47.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MNTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: -9.6 Max: 30.1
Current: -47.4
-48.2
30.1
GuruFocus has detected 4 Warning Signs with Momenta Pharmaceuticals Inc $MNTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MNTA Guru Trades in Q1 2016

Jim Simons 1,029,051 sh (+86.90%)
PRIMECAP Management 2,738,900 sh (unchged)
John Paulson Sold Out
Joel Greenblatt Sold Out
» More
Q2 2016

MNTA Guru Trades in Q2 2016

PRIMECAP Management 2,738,900 sh (unchged)
Jim Simons 364,670 sh (-64.56%)
» More
Q3 2016

MNTA Guru Trades in Q3 2016

Paul Tudor Jones 19,731 sh (New)
PRIMECAP Management 2,739,900 sh (+0.04%)
Jim Simons 292,800 sh (-19.71%)
» More
Q4 2016

MNTA Guru Trades in Q4 2016

Jim Simons 397,100 sh (+35.62%)
Paul Tudor Jones 23,129 sh (+17.22%)
PRIMECAP Management 2,739,900 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325414    SIC: 2836
Compare:NAS:SUPN, OTCPK:KHTRF, OTCPK:GNMLF, OTCPK:TWMJF, NAS:EGRX, NAS:SGYP, NAS:IPXL, NAS:PCRX, OTCPK:EVTCY, NAS:DEPO, NYSE:DPLO, OTCPK:NPPNY, NAS:AMPH, NYSE:LCI, NAS:RDUS, NAS:HRTX, OTCPK:APHQF, NAS:SCMP, NAS:FLXN, NAS:SCLN » details
Traded in other countries:LZ1.Germany,
Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease.

Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel therapeutics. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimilars product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 100 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.

Top Ranked Articles about Momenta Pharmaceuticals Inc

Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Humira and M923 show equivalent results in moderate-to-severe chronic plaque psoriasis patients
Momenta Pharmaceuticals (NASDAQ:MNTA) announced yesterday that the results from the “confirmatory, randomized, double-blind, multicenter study of M923 in adult patients with moderate-to-severe chronic plaque psoriasis” are equivalent to AbbVie's (NYSE:ABBV) Humira in terms of the therapy’s efficacy, safety and body’s immune response after a treatment period of 16 weeks. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.82
MNTA's PB Ratio is ranked lower than
64% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. MNTA: 2.82 )
Ranked among companies with meaningful PB Ratio only.
MNTA' s PB Ratio Range Over the Past 10 Years
Min: 1.34  Med: 2.98 Max: 13.69
Current: 2.82
1.34
13.69
PS Ratio 9.47
MNTA's PS Ratio is ranked lower than
82% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. MNTA: 9.47 )
Ranked among companies with meaningful PS Ratio only.
MNTA' s PS Ratio Range Over the Past 10 Years
Min: 1.83  Med: 14.71 Max: 55.5
Current: 9.47
1.83
55.5
EV-to-EBIT -9.59
MNTA's EV-to-EBIT is ranked lower than
99.99% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. MNTA: -9.59 )
Ranked among companies with meaningful EV-to-EBIT only.
MNTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.4  Med: -4.6 Max: 16.6
Current: -9.59
-52.4
16.6
EV-to-EBITDA -10.57
MNTA's EV-to-EBITDA is ranked lower than
99.99% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. MNTA: -10.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.3  Med: -5 Max: 14.8
Current: -10.57
-80.3
14.8
Current Ratio 6.30
MNTA's Current Ratio is ranked higher than
86% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. MNTA: 6.30 )
Ranked among companies with meaningful Current Ratio only.
MNTA' s Current Ratio Range Over the Past 10 Years
Min: 1.71  Med: 9.66 Max: 24.92
Current: 6.3
1.71
24.92
Quick Ratio 6.30
MNTA's Quick Ratio is ranked higher than
87% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MNTA: 6.30 )
Ranked among companies with meaningful Quick Ratio only.
MNTA' s Quick Ratio Range Over the Past 10 Years
Min: 1.71  Med: 9.66 Max: 24.92
Current: 6.3
1.71
24.92
Days Sales Outstanding 233.89
MNTA's Days Sales Outstanding is ranked lower than
90% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. MNTA: 233.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.32  Med: 78.92 Max: 233.89
Current: 233.89
36.32
233.89

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.50
MNTA's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. MNTA: -9.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -218.2  Med: -9.8 Max: -1.7
Current: -9.5
-218.2
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.19
MNTA's Price-to-Net-Cash is ranked higher than
66% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. MNTA: 4.19 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MNTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.07  Med: 4.18 Max: 7.88
Current: 4.19
2.07
7.88
Price-to-Net-Current-Asset-Value 3.06
MNTA's Price-to-Net-Current-Asset-Value is ranked higher than
67% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MNTA: 3.06 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MNTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.96  Med: 3.46 Max: 7.24
Current: 3.06
1.96
7.24
Price-to-Tangible-Book 2.82
MNTA's Price-to-Tangible-Book is ranked lower than
55% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. MNTA: 2.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MNTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.72  Med: 3.15 Max: 6.16
Current: 2.82
1.72
6.16
Price-to-Intrinsic-Value-Projected-FCF 7.09
MNTA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
77% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MNTA: 7.09 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MNTA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.86  Med: 4.82 Max: 7.09
Current: 7.09
1.86
7.09
Price-to-Median-PS-Value 0.64
MNTA's Price-to-Median-PS-Value is ranked higher than
73% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MNTA: 0.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.8 Max: 2.95
Current: 0.64
0.21
2.95
Earnings Yield (Greenblatt) % -10.40
MNTA's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MNTA: -10.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.4  Med: 26.6 Max: 78.3
Current: -10.4
-10.4
78.3

More Statistics

Revenue (TTM) (Mil) $109.6
EPS (TTM) $ -0.32
Beta1.96
Short Percentage of Float7.88%
52-Week Range $7.86 - 19.90
Shares Outstanding (Mil)71.31

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 141 176 286
EPS ($) -1.08 -0.98 0.92
EPS without NRI ($) -1.08 -0.98 0.92
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 05 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
[2/23] Today's Top 10 Long/Short Estimize Signal Scores Feb 23 2017
Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca Feb 23 2017
Momenta Tops Q4 Earnings, Shares Down on Warning Letter Feb 22 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Momenta... Feb 22 2017
Manufacturing Delay Of Generic Drug From Pfizer Inc. (PFE) A Relief For Teva Pharmaceutical... Feb 22 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta... Feb 22 2017
Momenta 4Q Net 60 Cents a Share Feb 22 2017
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Momenta... Feb 22 2017
Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22,... Feb 22 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Momenta... Feb 22 2017
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US :... Feb 22 2017
Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More Feb 22 2017
Momenta Pharma downgraded by Leerink Partners Feb 22 2017
2:08 am Momenta Pharma receives FDA warning letter for contracted Glatopa - approval of the Glatopa... Feb 22 2017
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and... Feb 21 2017
Edited Transcript of MNTA earnings conference call or presentation 21-Feb-17 1:00pm GMT Feb 21 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Momenta... Feb 21 2017
Momenta Pharma's Supply Partner Gets FDA Warning Feb 21 2017
Sarepta Leads Biotech Movers on Voucher Deal News Feb 21 2017
Momenta beats Street 4Q forecasts Feb 21 2017
Momenta Provides Year-End 2016 Corporate Update Jan 06 2017
Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs,... Jan 05 2017
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results Nov 02 2016
Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial... Nov 02 2016
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA®... Nov 02 2016
Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences Oct 31 2016
Momenta Pharmaceuticals Announces Date for Third Quarter 2016 Financial Results Conference Call and... Oct 20 2016
Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors Sep 23 2016
Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results Aug 04 2016
Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic... Aug 04 2016
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors Jun 23 2016
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody Jun 09 2016
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab)... Jun 08 2016
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in... Jun 04 2016
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare... May 25 2016
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting May 19 2016
Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results May 03 2016
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 03 2016
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences May 02 2016
Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference... Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)